Business Context and Reporting Period
Company: Church & Dwight Co., Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: July 2, 2004 (Second Quarter)
Key Event: On May 28, 2004, the Company completed the acquisition of the remaining 50% interest in Armkel, LLC from affiliates of Kelso & Company for approximately $253.7 million. Armkel was merged into the Company, and its results are consolidated from May 29, 2004. This transaction significantly altered the Company's segment structure and balance sheet.
Key Financial Metrics
| Metric (in thousands) | Q2 2004 | Q2 2003 | YTD 2004 | YTD 2003 |
|---|---|---|---|---|
| Net Sales | $340,785 | $256,263 | $636,776 | $504,561 |
| Gross Profit | $119,676 | $79,573 | $216,238 | $153,407 |
| Gross Margin % | 35.1% | 31.1% | 34.0% | 30.4% |
| Income from Operations | $41,428 | $25,049 | $79,888 | $53,830 |
| Net Income | $19,573 | $24,626 | $49,479 | $45,572 |
| Diluted EPS | $0.45 | $0.59 | $1.15 | $1.09 |
| Cash from Operations (YTD) | $78,199 | $43,528 | ||
| Total Debt (July 2, 2004) | $932,847 | |||
| Cash & Equivalents (July 2, 2004) | $119,561 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 33.0% in Q2 and 26.2% YTD. Growth was driven primarily by the inclusion of Armkel sales ($43.5M in Q2) and the Unilever oral care business acquired in late 2003 ($28.1M in Q2).
- Profitability: While operating income increased significantly due to acquisitions, Net Income for Q2 2004 decreased 20.5% compared to Q2 2003. This decline was primarily due to a $7.995 million loss on the early extinguishment of debt and a significant drop in "Equity in earnings of affiliates" ($9.7M decrease) as Armkel was consolidated rather than accounted for under the equity method.
- Balance Sheet: Total assets increased from $1.12 billion to $1.85 billion. Total debt more than doubled to $932.8 million to fund the Armkel acquisition and refinance existing obligations. Goodwill increased by approximately $302 million due to the acquisition.
- Segment Redefinition: Operating segments were redefined to Domestic Consumer, International Consumer, and Specialty Products Division (SPD) following the Armkel consolidation.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Debt Extinguishment: A one-time charge of $7.995 million was recorded for the loss on early extinguishment of debt.
- Impairment: A plant impairment charge of $1.5 million was recorded in Q2 2004.
- Inventory Step-Up: An inventory step-up charge of $4.1 million impacted gross margin in Q2 2004 related to the Armkel acquisition.
- Outlook & Investments: The Company announced an agreement to invest $30 million in a new entity to acquire Del Laboratories, Inc. (owner of the Orajel brand), with an option to acquire the business after three years. The transaction is expected to close in Q4 2004.
- Dividends & Stock Split: On August 6, 2004, the Company announced a 3-for-2 stock split and an increase in the annual dividend to $0.36 per share (pre-split), or $0.24 per share post-split.
- Risks & Contingencies:
- Legal: A Delaware court determined the fair value of shares in a prior merger (Carter-Wallace/Medpointe) at $24.47 per share. The Company faces a potential indemnification liability of approximately $3.9 million plus interest, with a maximum cap of $12 million.
- Regulatory: Ongoing FDA review regarding the labeling of condoms containing nonoxynol-9 (N-9). While the Company has implemented interim labeling, future restrictions could impact results.
- Accounting Changes: Proposed FASB rules (EITF Issue 04-8) regarding contingently convertible debt ("Co-cos") could have a dilutive effect on EPS starting in reporting periods ending after December 15, 2004.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new Credit Agreement leverage ratio (Total Debt to Adjusted EBITDA). The reported ratio was 3.42x (limit 4.25x) and interest coverage was 7.85x (minimum 3.0x).
- Acquisition Integration: Monitor the integration of Armkel and the Unilever oral care brands to ensure projected synergies and margin improvements materialize.
- Del Laboratories Transaction: Confirm the closing of the $30 million investment in Del Laboratories and the terms of the option to acquire the Orajel business.
- Legal Exposure: Track the final judgment order regarding the Carter-Wallace appraisal rights to confirm the exact liability amount.
- EPS Dilution: Assess the impact of the new accounting rules for contingently convertible debt on future diluted EPS calculations.